HealthCare Global Enterprises Ltd
- P/E
- 181.5x
- 52-week range
- 513.3 – 799.01
- ROE
- 3%
- ROCE
- 8%
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
HealthCare Global Enterprises Limited is an India-based cancer care provider. The Company offers cancer care, fertility treatment, advanced screening and diagnostic services, and tertiary care. It operates a cancer care network in India in terms of the total number of private cancer treatment centers under the brand HCG. The Company provides fertility treatment under its Milann brand. Its Milann fertility centers provide reproductive medicine services, including assisted reproduction, gynecological endoscopy and fertility preservation and follow a multidisciplinary and technology-focused approach to diagnosis and treatment. The Triesta brand offers oncology diagnostics, biomarker and translational research, and laboratory services. The Company operates a comprehensive cancer care center in Indore, Madhya Pradesh. It is also engaged in the radiation business in Indore, Madhya Pradesh. Its multispecialty hospitals deliver tertiary care for cardiac, bone and joint, brain, and spine.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →HealthCare Global Enterprises Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)181.5 against a typical 48.9: pricier than most peers (1st = cheapest).39th of 40
- Sales growth+13.4% against a typical +21.1% from a year earlier.25th of 34
- Profit growth+166.7% against a typical +13% from a year earlier.2nd of 31
- Share price, 3 months−12.6% against a typical −10.9%.19th of 34
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]A+ | Stable | 25 Mar 2026 |
| CARE | CARE A+ | Stable | 7 Jan 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 25 Mar 2026 | Reaffirmed | [ICRA]A+ | — | ICRA | ₹ 776.01 Cr. | |
| 7 Jan 2026 | Reaffirmed | CARE A+ | — | CARE | ₹ 615.24 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Nov 2026Upcoming | Financial Results | To consider and approve the unaudited financial results of the Company for the quarter and six months ended September 30, 2026. |
| 6 Aug 2026 | Financial Results/Other business matters | To consider and approve the unaudited financial results for the period ended Jun 30, 2026 and other business matters |
| 19 May 2026 | Financial Results/Other business matters | This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 19, 2026, to consider and approve inter-alia the Audited Financial Results (both Standalone and Consolidated) of the Company for the quarter and financial year ended March 31, 2026 ( Financial Results ). |
| 24 Feb 2026 | Fund Raising | Further to the intimation on the outcome of the meeting of the Board of Directors of the Company ( Board ) held on February 17, 2026 and in compliance with Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we hereby inform you that a meeting of the Board of Directors will be held on February 24, 2026, inter alia, to consider, discuss and decide various matters in connection with the Rights Issue, including the specific terms of the Rights Issue, such as the determination of the Rights Issue price and related payment mechanism, rights entitlement ratio, the record date and timing of the Rights Issue and other related matters, subject to the receipt of in-principle approval from the stock exchanges where the securities of the Company are listed or such other regulatory authorities as may be required. |
| 17 Feb 2026 | Fund Raising | To consider and approve inter alia, the proposal of fund raise by way of issuance of equity shares through Rights Issue. |
| 5 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 12 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 487 | 470 | 495 | 526 | 554 | 559 | 585 | 613 | 647 | 633 | 652 | 695 |
| Expenses | 402 | 391 | 403 | 435 | 451 | 470 | 480 | 505 | 524 | 524 | 527 | 573 |
| Operating Profit | 85 | 79 | 92 | 91 | 102 | 88 | 106 | 108 | 123 | 110 | 125 | 122 |
| OPM % | 17% | 17% | 19% | 17% | 18% | 16% | 18% | 18% | 19% | 17% | 19% | 18% |
| Other Income | 3 | 6 | 9 | 9 | 11 | 6 | 10 | 8 | 3 | −10 | −18 | 13 |
| Interest | 27 | 29 | 27 | 34 | 36 | 41 | 44 | 45 | 44 | 45 | 43 | 40 |
| Depreciation | 43 | 44 | 46 | 47 | 50 | 57 | 58 | 58 | 63 | 61 | 63 | 70 |
| Profit before tax | 18 | 11 | 28 | 19 | 28 | −3 | 14 | 12 | 20 | −6 | 1 | 25 |
| Tax % | 40% | 69% | 17% | 28% | 25% | −335% | 50% | 50% | −4% | 30% | −223% | 34% |
| Net Profit | 11 | 3 | 23 | 14 | 21 | 8 | 7 | 6 | 21 | −8 | 4 | 16 |
| EPS in Rs | 0.92 | 0.39 | 1.44 | 0.82 | 1.22 | 0.47 | 0.5 | 0.32 | 1.09 | −0.63 | 0.15 | 0.92 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 16%
- 5 Years
- 20%
- 3 Years
- 15%
- TTM
- 14%
- 10 Years
- 39%
- 5 Years
- 18%
- 3 Years
- −1%
- TTM
- 30%
- 10 Years
- 13%
- 5 Years
- 27%
- 3 Years
- 29%
- TTM
- —
- 10 Years
- −1%
- 5 Years
- 4%
- 3 Years
- 4%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| HealthCare Global Enterprises Ltd | ₹ 589.70 | — | 181.5x | — | 3% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.8x | 13.4x | 0% | 0% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 68.1x | 9.4x | 0% | 0% |
| Manipal Health Enterprises Ltd | ₹ 606.90 | ₹ 79,830 Cr. | 99.6x | 11.2x | 0% | 0% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 63.4x | 6.8x | 0% | 0% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 95.4x | 8.6x | 0% | 0% |
Management
- Manish Mattoo
- Chief Executive Officer, Executive Director
- Sanjeev Kumar
- Chief Financial Officer
- Manu Shankar Das
- Chief Marketing Officer
- Sunu Manuel Abey
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.